Stockscreener 앱 받기
2.76
2.60%
0.07
시간 외 거래:
2.76
전일 마감가:
$2.69
열려 있는:
$2.71
하루 거래량:
545.47K
Relative Volume:
1.26
시가총액:
$159.81M
수익:
$59.62M
순이익/손실:
$8.57M
주가수익비율:
23.19
EPS:
0.119
순현금흐름:
$-12.62M
1주 성능:
-1.08%
1개월 성능:
-3.50%
6개월 성능:
+19.48%
1년 성능:
+295.42%
1일 변동 폭
$2.6852
$2.85
1주일 범위
$2.50
$2.85
52주 변동 폭
$0.6562
$3.22
Spero Therapeutics Inc Stock (SPRO) Company Profile
명칭
Spero Therapeutics Inc
전화
857-242-1600
주소
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Compare SPRO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.76 | 155.76M | 59.62M | 8.57M | -12.62M | 0.119 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-23 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-10-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-01-22 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-09-29 | 개시 | Evercore ISI | Outperform |
| 2019-11-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-09-09 | 개시 | Janney | Buy |
| 2018-02-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-11-27 | 개시 | BofA/Merrill | Neutral |
| 2017-11-27 | 개시 | Oppenheimer | Outperform |
| 2017-11-27 | 개시 | Stifel | Buy |
모두보기
Spero Therapeutics Inc 주식(SPRO)의 최신 뉴스
Spero Therapeutics (SPRO) Q1 2026 Earnings: Why the Beat MattersCEO Earnings Statement - Newser
SPRO Technical Analysis | Trend, Signals & Chart Patterns | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Spero Therapeutics, Inc. Common Stock (SPRO) Stock Price Today & Analysis - Gotrade
Is Spero Therapeutics (SPRO) 110.3% Overvalued After Q1 2026 Ear - GuruFocus
Spero Therapeutics 1Q Loss $7.2M >SPRO - Moomoo
Spero Therapeutics Q1 revenue drops on decreased clinical activity - TradingView
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update - The Manila Times
Spero Therapeutics (NASDAQ: SPRO) leans on GSK-partnered tebipenem ahead June 2026 FDA date - Stock Titan
Spero Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Spero Therapeutics (SPRO) trims Q1 2026 loss ahead key tebipenem FDA date - Stock Titan
FDA to rule June 18 on Spero oral antibiotic for severe UTIs - Stock Titan
TradingKey - TradingKey
MSN Money - MSN
Number of shareholders of Spero Therapeutics, Inc. – NASDAQ:SPRO - TradingView
SPRO SEC FilingsSpero Therapeuti 10-K, 10-Q, 8-K Forms - Stock Titan
SPRO FINAL DEADLINE TODAY: ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important July 25 Deadline in Securities Class ActionSPRO - TMX Newsfile
Spero Therapeutics (SPRO.US) will release its earnings report after the market closes on May 13. - 富途牛牛
Spero Therapeutics (SPRO) officer sells shares for RSU tax obligations - Stock Titan
Spero Therapeutics CEO sells $63,352 in company stock By Investing.com - Investing.com Australia
Spero Therapeutics CEO sells $63,352 in company stock - Investing.com India
SPRO: The fleeting Sparrow - Moomoo
No call planned as Spero sets May 13 for Q1 results update - Stock Titan
Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 - GlobeNewswire
SPRO Stock Price, Quote & Chart | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Significant Growth in Short Interest - MarketBeat
Best Momentum Stock to Buy for October 10th - MSN
Spero Therapeutics (NASDAQ: SPRO) 2026 proxy adds stock increase and new incentive plan - Stock Titan
Spero Therapeutics (SPRO) price target decreased by 20.00% to 4.08 - MSN
[ARS] Spero Therapeutics, Inc. SEC Filing - Stock Titan
ROSEN, Top Ranked Investor Counsel, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class ActionSPRO - TMX Newsfile
Spero Therapeutics (SPRO) Stock Volume Spike Alert (Builds on Momentum) 2026-04-20Open Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
Spero Therapeutics (SPRO) Stock Insider Buying (Market Focus) 2026-04-18Algo Picks - Cổng thông tin điện tử tỉnh Lào Cai
SPRO Forecast, Price Target & Analyst Ratings | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Spero Therapeutics Stock Rises Above 50-Day Moving Average - National Today
Spero Therapeutics (NASDAQ:SPRO) Share Price Passes Above 50 Day Moving AverageWhat's Next? - MarketBeat
Spero Therapeutics (NASDAQ: SPRO) asks shareholders to double authorized shares to 240M - Stock Titan
Portfolio Shifts: Is Spero Therapeutics Inc stock showing strong momentum2026 Rallies & AI Forecasted Entry/Exit Points - baoquankhu1.vn
MACD Signal: Does Spero Therapeutics Inc have pricing power2026 Growth vs Value & Verified Swing Trading Watchlist - baoquankhu1.vn
Can Spero Therapeutics (SPRO) Stock increase dividends | Price at $2.63, Down 5.40%Hot Community Stocks - Newser
Non Tuberculous Mycobacterial Infections Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharmaceuticals - Barchart.com
Is Spero Therapeutics (SPRO) Stock undervalued by the market | Price at $2.73, Up 0.55%Crowd Breakout Signals - Newser
Market Overview: Will Spero Therapeutics Inc benefit from seasonality2026 Pullbacks & Capital Efficiency Focused Ideas - baoquankhu1.vn
Market Review: What is the PEG ratio of Spero Therapeutics IncInflation Watch & Safe Capital Growth Stock Tips - baoquankhu1.vn
Is Spero Therapeutics (SPRO) Stock Reacting to Market | Price at $2.73, Up 2.43%Institutional Flow - Newser
Spero Therapeutics Stock Rises Above 50-Day Average - National Today
Spero Therapeutics Inc (SPRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):